23
© Hagit Messer-Yaron, 2011 Prof. Hagit Messer-Yaron [email protected] Novi Sad, Oct. 12, 2011

Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

  • Upload
    vudan

  • View
    214

  • Download
    2

Embed Size (px)

Citation preview

Page 1: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Prof. Hagit Messer-Yaron

[email protected]

Novi Sad, Oct. 12, 2011

Page 2: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Technology Transfer in Countries in

Transition: Policy and Recommendations

1. Introduction, background and implementation

1.1 What is Technology Transfer and who benefits from it?

1.2 Metamorphosis of an invention – from scientific research to a

product.

2. Best Practice Examples: Technology Transfer in Israel

2.1 National and institutional policy

2.2. Bridging the "Development Gap" – providing proof of

principle

2.3 Technology entrepreneurship in a research university

3. In the Public Interest: Guidelines for Commercializing

University Technology in Countries in Transition

3.1 Case study on technology transfer in countries in transition

3.2 Guidelines and recommendations

Page 3: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Industry vs. university

industry

university knowledge

knowledge

money

money

Researchers (people!),

Faculties,

Administration,

etc.

Entrepreneurs

VCs

Productions

Marketing

Management

Stocks holders

etc.

TT

Page 4: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

The Death Valley

Academia

Science

" Valley Death "

Products

Industry

Page 5: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Bridging over the “Death Valley”

Structured relations between

universities and industries:

R&D agreements

Licensing deals

New venture formation/Spin-offs

Other:

Individual entrepreneurship

Page 6: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

The technology transfer process

Revenues IDF

Discovery &

Innovation Evaluation

Patenting &

Marketing

Strategy

R&D agreement

Or

Licensing deal

Or

Spin-off

Follow Up

on Contract

Academic Basic and

Applied Research

publications

To inventors

Individual entrepreneurship

To Industry

3 2

1

Page 7: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Academia

Science

" Valley Death "

Products

Industry

R&D agreements

Research and development

agreements

Page 8: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Example: ’s 4X technology SanDisk's Press Release:

Milpitas, Calif., Oct. 13, 2009 - SanDisk Corporation (NASDAQ: SNDK), the global

leader in flash memory cards, today announced it has begun production shipments of flash

memory cards based on the company's advanced X4 flash memory technology. This

innovative new technology holds four bits of data in each memory cell, twice as many as

the cells in conventional multi-level cell (MLC) NAND (2-bits-per-cell) memory chips.

Tel Aviv University (TAU) had provided a significant contribution to the X4 advanced

error correcting and digital signal processing technology, which was licensed

exclusively to SanDisk by Ramot at Tel Aviv University Ltd., TAU's technology transfer

company. "X4 took five years of development at SanDisk, and the finished product is a

testament to the hard work and collaboration of the parties involved," said Dr. Ze'ev

Weinfeld, Ramot's CEO. "Once we created the basic approach, SanDisk brought this to

fruition by developing its advanced X4 controller and matching it with its advanced 43nm,

64Gb X4 memory thus making full X4 product implementation possible. This highlights

the benefit commercial companies may gain from cooperation with TAU, building on

our pool of talent and expertise.“ http://www.sandisk.com/about-sandisk/press-room/press-releases/2009/2009-10-13-sandisk-ships-world%E2%80%99s-first-flash-

memory-cards-with-64-gigabit-x4-(4-bits-per-cell)-nand-flash-technology

Page 9: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Licensing deals

Academia

Science

" Valley Death "

Products

Industry

Licensing deals

Page 10: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Example: Merz Pharmaceuticals and Tel Aviv

University Become Partners in Novel Drug Technology

Development for Treatment of Alzheimer's

“ Tel Aviv, Israel/Frankfurt am Main, Germany – July 10,

2007. – A novel drug technology to treat Alzheimer's

disease developed by Prof. Ehud Gazit and his team of

researchers at the George S. Wise Faculty of Life Sciences

at Tel Aviv University (TAU), Israel, was licensed to

Merz Pharmaceuticals GmbH by Ramot at Tel Aviv

University Ltd., the University’s technology transfer

company. The worldwide exclusive license deal includes

an upfront fee and milestone payments as well as royalties

on future sales.”

Page 11: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Academia

Science

" Valley Death "

Products

Industry

Spin offs

New venture formation /

Spin-offs

Page 12: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Example:

Page 13: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Individual entrepreneurship

Is there a room for Individual entrepreneurship

of university professors, outside the structural

technology transfer process?

Is there a need for Individual entrepreneurship

of university professors, outside the structural

technology transfer process?

Can it be done?

Page 14: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Individual entrepreneurship

Why YES

The researcher feels

responsible and is more

motivated

More efficient knowledge

transfer to the industry.

Why NO

Public to Private

Potential conflict of

interest

May be inefficient in the

longer term

=> Doable, but calls for coherent

policy and clear rules of operation

Page 15: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Issues to be considered

Ownership of IP: service inventions?

If YES – set up an agreement between all

parties to reflect freedom of operation vs.

obligation.

If no – consider the statues of future IP.

Conflict of interests, conflict of commitment:

Set up clear rules regarding the use of

university resources, researcher own time

resources; involvements of students.

Page 16: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Example #1: Weizmann Inst. Rules

of IP: anything IS a service invention

Page 17: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Weizmann’s pipeline:

50-70Patent applications/year.

20-30 Licensing agreements/year.

2-5 Spin-off companies/year.

Team of 17 employees with an annual budget of €2.3M. More

than €1M are spend on patent filing and prosecution.

Successful Technology Transfer

Page 18: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Selected Weizmann Success Stories

QuantomiXTM | QX Capsule

Copaxone® | Teva

Rebif

® | Merck Serono

Encryption Algorithm | NDS

GeneCardsTM | XenneX

NanoLubTM | Nanomaterials

Dunaliella | Nikken Sohonsha

ErbituxTM | ImClone

Total sale of Weizmann based products €6 Bilion/year

Page 19: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

With THE BEST Science

MONDAY, JULY 4, 2011

Weizmann rated best academic

workplace outside US

The 150,000-square-meter leafy, landscaped campus of the

Weizmann Institute of Science in Rehovot has again been

named in The Scientist magazine’s annual survey as the

“best place to work in academia” outside the US.

Page 20: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Example #2 – TAU’s policy regarding

Individual Entrepreneurship As in the Weizmann inst., the default is that a researcher’s invention is a

service (university) invention.

A claim that the invention is not DUE to his/her “service” and it is NOT a

university invention is studied and an invention can be defined (by the

university) as a non-service invention

* => The researcher has a complete freedom of operation (subject to NO

COI/COC)

With a service invention, there are cases where the University decides that

it is not interested in commercialize the invention, and the IP is assigned to

him/her with an obligation to share with the university 20% of his/her

income.

* => The researcher has a complete freedom of operation (subject to NO

COI/COC)

Page 21: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Dealing with Future IP

Once freedom of operation (FOO) were given to an

individual researcher, based on existing IP, the main

challenge is dealing with future IP created by the

researcher.

The policy should leave FOO together with the rights

of the university w.r.to its IP.

In TAU, a specific regime where FOO is guaranteed

has been formally defined, with on obligation for full

disclosure to the University, and sharing revenues

from activities outside this regime.

Page 22: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Page 23: Prof. Hagit Messer-Yaron - Завод за интелектуалну … Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment

© Hagit Messer-Yaron, 2011

Legal

Infrastructure

Policy Implementation

Personnel

What is needed for successful TT?